ClinicalTrials.gg
RecruitingNCT06855433CRYSTALLIZEUpdated Sep 21, 2026

Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment

A Phase 2 interventional study of Colchicine Pill and Placebo in CPPD - Calcium Pyrophosphate Deposition Disease, sponsored by Brigham and Women's Hospital. Recruiting at 5 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if colchicine reduces levels of proteins indicating inflammation in the blood in individuals with calcium pyrophosphate deposition (CPPD) disease. The trial will also test the effect of colchicine on joint symptoms in CPPD disease. The main questions it aims to answer are:

  • Does colchicine reduce the level of interleukin 18 (IL-18) in the blood of individuals with CPPD disease?
  • Does colchicine reduce pain scores in individuals with CPPD disease?

Researchers will compare colchicine once daily to a placebo (a look-alike pill that contains no drug) to see if colchicine works to treat CPPD disease.

Participants will:

  • Take colchicine or a placebo every day for 6 months
  • Visit the clinic 3 times in 6 months for joint examinations, surveys, and blood tests. Each visit will last 2-3 hours.
  • Speak on the telephone with researchers for about 4 times over 6 months. Each phone call will last about 5 minutes.
02

Conditions studied

  • CPPD - Calcium Pyrophosphate Deposition Disease

Keywords

  • colchicine
  • CPPD disease
  • calcium pyrophosphate
  • pseudogout
03

In context

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.

Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written
  • Fulfill ACR/EULAR 2023 CPPD classification criteria
  • Acute or chronic joint inflammation currently or in the past 3 months, not attributable to another condition (Joint Inflammation defined as: At least 1 joint this is swollen, red, or warm to the touch; with or without corresponding tenderness)
  • Pain visual analog scale (pain VAS) >=30 at screening

Exclusion criteria

Exclusion Criteria:

  • Age \<40 years
  • Chronic diarrhea
  • Gout, rheumatoid arthritis, psoriatic arthritis, or cirrhosis
  • Ongoing use of colchicine and unwilling to undergo a 30-day (note: patients using colchicine at screening can enroll if they agree to a 30-day wash-out before randomization)
  • Pregnant or breast-feeding
  • Use of methotrexate, hydroxychloroquine, tocilizumab or canakinumab in the past 4 weeks
  • Use of anakinra, oral , or intra-articular steroid in the past 1 week
  • Ongoing use of strong inhibitors per FDA package insert for colchicine
  • Ongoing use of P-glycoprotein inhibitors per FDA package insert for colchicine
  • Known allergy to colchicine
  • Planned joint surgery in the next 6 months
  • CPPD clinical presentation isolated to Crowned Dens Syndrome with no additional peripheral joint involvement
  • Screening labs with any of the following:

    1. \< 9 g/dL
    2. WBC \<3 x 10\^9/L
    3. \<110 x10\^9/L
    4. (CrCl) \<30 mL/min
    5. or AST >3x (ULN)
  • Patient is considered by investigator to be an unsuitable candidate for the study for any reason
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Colchicine

    Colchicine

    Drug: Colchicine Pill

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Colchicine 0.6mg tab, overencapsulated to match placebo capsule, taken by mouth once daily

  • DrugPlacebo

    Placebo capsule, taken by mouth once daily

06

What researchers measure

Primary outcomes

  1. Interleukin 18 (IL-18)

    Serum IL-18

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Serum IL-1b

    Serum IL-1b

    Time frame: Baseline and Week 24

  2. Serum IL-17A

    Serum IL-17A

    Time frame: Baseline and Week 24

  3. High-sensitivity C-reactive protein (hsCRP)

    High-sensitivity C-reactive protein in blood

    Time frame: Baseline and Week 24

  4. IL-1b gene signature expression in PBMCs

    Expression of a panel of genes involved in IL-1b production or signaling, as percentage of total gene expression per cell

    Time frame: Baseline and Week 24

  5. Immune cell population frequencies

    Immune cell clusters among PBMCs

    Time frame: Baseline and Week 24

  6. Pain visual analog scale (pain VAS)

    Severity of pain from CPPD disease/pseudogout, both at rest and with activity, in the past 7 days (range 0-100mm, with 0 indicating no pain)

    Time frame: Baseline, Week 12, Week 24

  7. Brief Pain Inventory (Short Form)

    Brief Pain Inventory includes two sub-scores: Pain Severity Score (range 0-10, with 0 indicating no pain in the past 24 hours) and Pain Interference Score (range 0-10, with 0 indicating no interference in the past 24 hours)

    Time frame: Baseline, Week 12, Week 24

  8. Pain in the past week (PEG [pain intensity [P], interference with enjoyment of life [E], and interference with general activity [G])

    3 question instrument, range 0-10, with 0 indicating no pain and no interference in the past week

    Time frame: Baseline, Week 12, Week 24

  9. Patient Reported Outcome Measurement Information System (PROMIS)-Physical Function

    PROMIS-Physical Function Short Form 10a (T-score range 0-100, with higher scores indicating better physical function)

    Time frame: Baseline, Week 12, Week 24

  10. Patient Global Assessment of Response to Treatment

    5 point Likert scale

    Time frame: Week 12, Week 24

  11. Patient Global Assessment

    Patient Global Assessment of CPPD Disease Activity (range: 0-10)

    Time frame: Baseline, Week 12, Week 24

  12. Physician Global Assessment

    Physician's Global Assessment of CPPD Disease Activity (range: 0-10)

    Time frame: Baseline, Week 12, Week 24

  13. Flare count

    Number of acute calcium pyrophosphate crystal arthritis flares

    Time frame: Week 12, Week 24

  14. Adverse events

    Number of expected adverse events and unexpected adverse events

    Time frame: Week 12, Week 24

  15. Tender Joint Count

    Tender Joint Count

    Time frame: Baseline, Week 12, Week 24

  16. Swollen Joint Count

    Swollen Joint Count

    Time frame: Baseline, Week 12, Week 24

07

Study locations

5 of 5 sites recruiting
  • University of Alabama - Birmingham
    Birmingham, Alabama 35233, United States
    Recruiting
    • Shelby Gontarz, Clinical Research Coordinator · Contactsgontarz@uab.edu
    • Clementino Vong Do Rosario, Clinical Research Coordinator · Contactcvongdorosario@uabmc.edu · (205) 975-6410
    • Angelo Gaffo, MD, MsPH · Principal investigator
  • University of California - Los Angeles
    Los Angeles, California 90095, United States
    Recruiting
    • Michelle Ramirez, Clinical Research Coordinator · ContactMichelleRa@mednet.ucla.edu · (310) 825-9956
    • Aima Ohiwerei, Clinical Research Coordinator · ContactAOhiwerei@mednet.ucla.edu · (310) 825-2598
    • John Fitzgerald, MD, PhD · Principal investigator
  • Boston University Medical Center/Boston Medical Center
    Boston, Massachusetts 02118, United States
    Recruiting
    • Sayali Dhamne, Clinical Research Coordinator · Contactscdhamne@bu.edu · (617) 358-9655
    • Sneha Sinha, Clinical Research Coordinator · Contactsneha@bu.edu
    • Tuhina Neogi, MD · Principal investigator
    • Maureen Dubreil, MD · Sub investigator
  • Brigham and Women's Hospital
    Boston, Massachusetts 02118, United States
    Recruiting
    • Brenna Sharp de Flores, Senior Research Coordinator · Contactbsharp@bwh.harvard.edu · 617-732-6277
    • Sara Tedeschi, MD, MPH · Principal investigator
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Kiley Timler, Clinical Research Coordinator · Contactktimler@mcw.edu · (414) 955-6875
    • Ann Rosenthal, MD, FACP · Principal investigator
    • Viktoriya Sabchyshyn, DO · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Apr 2030, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Mar 3, 2025
StartActual
Aug 12, 2026
Primary completionEst.
Apr 30, 2030
CompletionEst.
Sep 30, 2030
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06855433
Collaborators
Rheumatology Research Foundation
Responsible party
Sara Tedeschi, M.D., M.P.H. (Assistant Professor of Medicine, Brigham and Women's Hospital) — Principal investigator
First posted
Mar 3, 2025
Start date
Aug 12, 2026
Primary completion
Apr 30, 2030 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Sep 21, 2026

Study contacts

Brenna Sharp de Flores, Senior Research Coordinator
Contact
bsharp@bwh.harvard.edu
617-732-6277
Sara Tedeschi, MD, MPH
Contact
stedeschi1@bwh.harvard.edu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion